Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes

Pharmacogenetics

Volumn 7, Issue 1, 1997, Pages 1-10

  Rochat, Bertrand ^a   Amey, Marlyse ^a   Gillet, Michel ^b   Meyer, Urs A ^c   Baumann, Pierre ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

biotransformation; citalopram; CYP1A2; CYP2C19; CYP2D6; CYP3A4; enantiomer; human liver; microsomes; SSRI

Indexed keywords

CITALOPRAM; CYTOCHROME P450; DRUG METABOLITE; FLUVOXAMINE; ISOENZYME;

ARTICLE; BIOTRANSFORMATION; DEMETHYLATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; STEREOCHEMISTRY; STEREOSPECIFICITY;

ARYL HYDROCARBON HYDROXYLASES; B-LYMPHOCYTES; CELL LINE; CITALOPRAM; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; STEREOISOMERISM; TRANSFECTION;

EID: 0030957623     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199702000-00001     Document Type: Article

References (42)

1. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597-604.
2. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995: 6, 287-295.
3. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M. A double-blind placebo controlled study of citalopram with and without lithium in the treatment of therapy-resistent depressive patients. J Clin Psychopharmacol 1996: in press.
4. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993: 45, 1211-1214.
5. Chang TKH, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytrochromes P450. Arch Bochem Biophys 1994: 311, 437-442.
6. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994: 37, 237-242.
7. Conus P, Bondolfi G, Eap CB, Macciardi F, Baumann P. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry 1996: 29, 1-3.
8. Coudoré F, Fialip J, Eschalier A, Lavarenne J. Mice plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after half-life repeated administration. Comparison with acute administration. Fundam Clin Pharmacol 1994: 8, 525-531.
9. Coutts RT, Su P, Baker GB, Daneshtalab M. Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observations on metabolite stability. J Chromatogr Biomed Appl 1993: 615, 265-272.
10. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992: 34, 262-265.
11. Dayer P, Kronbach T, Eichelbaum M, Meyer UA. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation - characterization of bufuralol 1′-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 1987: 36, 4145-4152.
12. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydrolase in humans. Biochemistry 1994: 33, 1743-1752.
13. Guengerich FP, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986: 30, 287-295.
14. Härtter S, Arand M, Oesch F, Hiemke C. Non-competitive inhibition of clomipramine N-demethylation of fluvoxamine. Psychopharmacology 1995: 117, 149-153.
15. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplitication. Lancet 1990: 336, 529-32.
16. Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatoloxicity caused by Atrium(R), a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J Hepatol 1994: 21, 1075-1079.
17. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. Short communication. J Neurol Transm Gen Sect 1992: 88, 157-160.
18. Jensen KG, Poulsen HE, Doehmer J, Loft S. Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. Pharmacol Toxicol 1995: 76, 286-288.
19. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Molec Pharmacol 1993: 43, 827-832.
20. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951: 193, 265-275.
21. Mautz DS, Nelson WL, Shen DD. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab Dispos 1995: 23, 513-517.
22. Milne RJ, Goa KL, Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991: 41, 450-477.
23. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors - evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995: 23, 154-158.
24. Oyehaug E, Ostensen ET, Salvesen B. High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr Biomed Appl 1984: 308, 199-208.
25. Pellinen P, Honkakoski P, Stenbäck F, Niemitz M, Alhava E, Pelkonen O, Lang MA, Pasanen M. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Europ J Pharmacol - Environ Toxicol Pharmacol Section 1994: 270, 35-43.
26. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994: 56, 471-476.
27. Petersen K-U. Review article: Omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 1995: 9, 1-9.
28. Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brosen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995: 39, 151-159.
29. Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1995a: 17, 273-279.
30. Rochat B, Amey M, van Gelderen H, Testa B, Baumann P. Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 1995b: 7, 389-395.
31. Rodrigues AD. Commentary - use of in vitro human metabolism studies in drug development - an industrial perspective. Biochem Pharmacol 1994: 48, 2147-2156.
32. Sewell RB, Brook CW, Mihaly GW, Morgan DJ, Smallwood RA. Intracellular binding is an important determinant of the avid hepatic uptake of the high clearance drug omeprazole. Biochem Pharmacol 1994: 48, 846-849.
33. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 50 Caucasians. J Pharmacol Exp Ther 1994: 270, 414-423.
34. Sindrup SH, Brosen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993: 15, 11-17.
35. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992: 34, 256-261.
36. Szegedi A, Wiesner J, Hiemke C, Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995: 15, 141-143.
37. Uehlinger C, Nil R, Amey M, Baumann P, Dufour H. Citalopramlithium combination treatment of elderly depressed patients: a pilot study. Int J Ger Psychiatry 1995: 10, 281-287.
38. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993: 24, 203-220.
39. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P. fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine, and neuroleptics in phenotyped patients. Pharmacol Res 1995: 31, 347-353.
40. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants. and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994a: 268, 1278-1283.
41. Von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994b: 34, 1222-1227.
42. Von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995: 15, 125-131.